ACT Brief: Bayesian Methods Drive Adaptive Trials, Digital Endpoints Gain Regulatory Footing, and FDA Cracks Down on Compounded GLP-1 Marketing

In today's ACT Brief, we explore how Bayesian approaches are powering studies in rare disease and pediatrics, a major public-private initiative is standardizing digital endpoints for regulatory acceptance, and the FDA intensifies enforcement against misleading GLP-1 marketing.